Paclitaxel treatment for non small cell lung cancer.

It talk about Paclitaxelthe median age was 57 years (range 29 to 75 years)
Paclitaxel (Taxol) is another main drug used forand the median Eastern Co-Operative Oncology
treatment non small cell lung cancer, Paclitaxel hasGroup performance status was one. Most of the
since been made by synthetically modifying anpatients had stage IV (34) adenocarcinoma (31) with
intermediate substance isolated from yew needleslow differentiation (28). The median number of
using toxic solvents or by fermenting cell cultures.chemotherapy cycles was three, with a range of one
Paclitaxel was approved by the Food and Drugto eight.
Administration (FDA) in 1992.There is side effect of Paclitaxel, Suppression of
Paclitaxel is originally extracted from the bark of thebone marrow function is the principal adverse side
Pacififc yew tree ( Taxus brevifolia) and Paclitaxeleffect associated with paclitaxel treatment. Blood
belongs to a group of chemicals called taxoids.tests will allow a doctor to determine if there is
Docetaxel , a taxoid found in the English yew treeadequate bone marrow function to begin or continue
(Taxus baccata ) ), is similar to paclitaxel in terms oftreatment. Hypersensitivity may also occur during
chemical structure and biological action.treatment. Premedication is administered prior to
 60 patients fulfilling all eligibility criteria entered thistreatment to help alleviate this side effect. Additional
study. All patients received paclitaxel 175 mg/m2 as aside effects, including fever , infection, nausea,
three-hour infusion, and carboplatin dosed to an areavomiting, increase or decrease in blood pressure,
under the concentration-time curve of seven, everydiarrhea , weight loss , pain, and hair loss (alopecia)
three weeks. No granulocyte colony-stimulating factormay occur.
was given. Of the 56 male and four female patients,